FDA To Lower Scrutiny Of CMV Tests Used In Transplant Patients
Executive Summary
A proposed rule from the US agency would move the in vitro diagnostics from high-risk class III to class II with special controls, eliminating the requirement for a PMA.
You may also be interested in...
US FDA Panel To Meet on Transplant IVDs, Test For Managing Antibiotics
The agency's microbiology devices advisory panel will hold a two-day meeting next month focused on classification of transplant IVDs and potential 510(k) requirements for a test that can help detect and monitor sepsis and other bacterial infection.
Regulatory Science Tools For Phantoms, Lab Methods Added To US FDA Catalog
The regulatory tools are for use in medical device development.
US FDA, NIST Join Forces To Improve Manufacturing, Prevent Drug And Device Shortages
The focus on innovative manufacturing will also include a new clearinghouse to share info about advanced manufacturing technology within the US agency’s device center.
Need a specific report? 1000+ reports available
Buy Reports